[HTML][HTML] Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell leukemia
X Li, X Guo, Y Zhu, G Wei, Y Zhang, X Li, H Xu, J Cui… - Molecular Therapy, 2021 - cell.com
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
[HTML][HTML] Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
X Li, X Guo, Y Zhu, G Wei, Y Zhang, X Li, H Xu… - Molecular …, 2021 - ncbi.nlm.nih.gov
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
X Li, X Guo, Y Zhu, G Wei, Y Zhang… - … therapy: the journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
X Li, X Guo, Y Zhu, G Wei, Y Zhang… - Molecular …, 2021 - mayoclinic.elsevierpure.com
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.
X Li, X Guo, Y Zhu, G Wei, Y Zhang, H Xu… - … Therapy: the Journal …, 2020 - europepmc.org
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
[HTML][HTML] Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
X Li, X Guo, Y Zhu, G Wei, Y Zhang, X Li, H Xu, J Cui… - Molecular Therapy, 2021 - Elsevier
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …